Christos Vaklavas

Sep 25, 2024 | targetedonc.com | Christos Vaklavas

Christos Vaklavas, MD, associate professor and physician leader in breast cancer at the Huntsman Cancer Institute in Salt Lake City, Utah, discusses the results of the TROPION-Breast01 trial (NCT05104866) of datopotamab deruxtecan (dato-DXd) in patients with metastatic breast cancer.

Sep 14, 2024 | nature.com | Katia Khoury |Hope Rugo |Rita Nanda |Alexandra Zimmer |Judy Boughey |Christos Vaklavas | +11 more

AbstractAmong the goals of patient-centric care are the advancement of effective personalized treatment, while minimizing toxicity. The phase 2 I-SPY2.2 trial uses a neoadjuvant sequential therapy approach in breast cancer to further these goals, testing promising new agents while optimizing individual outcomes. Here we tested datopotamab–deruxtecan (Dato-DXd) in the I-SPY2.2 trial for patients with high-risk stage 2/3 breast cancer.

Sep 13, 2024 | nature.com | Rita Nanda |Hope Rugo |Judy Boughey |Kevin Kalinsky |Christos Vaklavas |Claudine Isaacs | +8 more

AbstractSequential adaptive trial designs can help accomplish the goals of personalized medicine, optimizing outcomes and avoiding unnecessary toxicity.